<?xml version="1.0" encoding="UTF-8"?>
<rdf:RDF xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns="http://purl.org/rss/1.0/"
xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:taxo="http://purl.org/rss/1.0/modules/taxonomy/"
xmlns:EMSArticle="http://webdoc.advanstar.com/rss/module/EMSArticle"
xmlns:sy="http://purl.org/rss/1.0/modules/syndication/" xmlns:dc="http://purl.org/dc/elements/1.1/">
  <channel rdf:about="http://www.pharmexec.com/pharmexec/servlet/pharmexec_48330.rss?id=48330">
    <title>Pharmaceutical Executive - Europe: Symons</title>

    <link>http://www.pharmexec.com/pharmexec/Europe%3A+Symons/Article/list/48330</link>

    <description>The publisher of Pharmaceutical Executive brings visitors PharmExec.com, which serves up a daily dose
    of news and features from the world of pharma business and marketing.</description>

    <items>
      <rdf:Seq>
        <rdf:li
        resource="http://www.pharmexec.com/pharmexec/Europe+Features/Nycomed-licensing-for-long-term-success/ArticleStandard/Article/detail/610864?contextCategoryId=48330&amp;ref=25" />

        <rdf:li
        resource="http://www.pharmexec.com/pharmexec/Europe%3A+Symons/The-million-dollar-question/ArticleStandard/Article/detail/603322?contextCategoryId=48330&amp;ref=25" />

        <rdf:li
        resource="http://www.pharmexec.com/pharmexec/Europe%3A+Symons/Towards-Pharma-Physician-Transparency/ArticleStandard/Article/detail/603323?contextCategoryId=48330&amp;ref=25" />

        <rdf:li
        resource="http://www.pharmexec.com/pharmexec/Europe%3A+Symons/A-True-Industry-Academia-Model/ArticleStandard/Article/detail/603324?contextCategoryId=48330&amp;ref=25" />
      </rdf:Seq>
    </items>

    <dc:date>2013-06-18T06:53:11Z</dc:date>
  </channel>

  <item
  rdf:about="http://www.pharmexec.com/pharmexec/Europe+Features/Nycomed-licensing-for-long-term-success/ArticleStandard/Article/detail/610864?contextCategoryId=48330&amp;ref=25">

    <title>Nycomed: licensing for long-term success</title>

    <link>
    http://www.pharmexec.com/pharmexec/Europe+Features/Nycomed-licensing-for-long-term-success/ArticleStandard/Article/detail/610864?contextCategoryId=48330&amp;ref=25</link>

    <description>Gerhard Symons asks Dr Carlos de Sousa, Vice President Licensing at Nycomed (Zurich) about the firm's
    in-licensing activities, and what differentiates it from its mid-tier and Big Pharma competitors.</description>

    <dc:date>2009-07-21T04:00:00Z</dc:date>

    <EMSArticle:flashImageUrl>
    http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/292009/610864null</EMSArticle:flashImageUrl>

    <EMSArticle:contentFormat>HTML</EMSArticle:contentFormat>
  </item>

  <item
  rdf:about="http://www.pharmexec.com/pharmexec/Europe%3A+Symons/The-million-dollar-question/ArticleStandard/Article/detail/603322?contextCategoryId=48330&amp;ref=25">

    <title>The million dollar question</title>

    <link>
    http://www.pharmexec.com/pharmexec/Europe%3A+Symons/The-million-dollar-question/ArticleStandard/Article/detail/603322?contextCategoryId=48330&amp;ref=25</link>

    <description>Gerhard Symons realises that just one simple question can expose complex tensions between short-term
    profit motive, long-term market building and perception management of the industry.</description>

    <dc:date>2009-03-31T04:00:00Z</dc:date>

    <EMSArticle:flashImageUrl>
    http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/242009/603322null</EMSArticle:flashImageUrl>

    <EMSArticle:contentFormat>HTML</EMSArticle:contentFormat>
  </item>

  <item
  rdf:about="http://www.pharmexec.com/pharmexec/Europe%3A+Symons/Towards-Pharma-Physician-Transparency/ArticleStandard/Article/detail/603323?contextCategoryId=48330&amp;ref=25">

    <title>Towards Pharma-Physician Transparency</title>

    <link>
    http://www.pharmexec.com/pharmexec/Europe%3A+Symons/Towards-Pharma-Physician-Transparency/ArticleStandard/Article/detail/603323?contextCategoryId=48330&amp;ref=25</link>

    <description>This month, the Royal College of Physicians wil recommend a 'new covenant' between industry,
    clinicians and patients. The ABPI's Dr Richard Tiner, a working party member on the report, tells Gerhard Symons
    why transparency is key.</description>

    <dc:date>2009-03-03T05:00:00Z</dc:date>

    <EMSArticle:flashImageUrl>
    http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/242009/603323null</EMSArticle:flashImageUrl>

    <EMSArticle:contentFormat>HTML</EMSArticle:contentFormat>
  </item>

  <item
  rdf:about="http://www.pharmexec.com/pharmexec/Europe%3A+Symons/A-True-Industry-Academia-Model/ArticleStandard/Article/detail/603324?contextCategoryId=48330&amp;ref=25">

    <title>A True Industry-Academia Model</title>

    <link>
    http://www.pharmexec.com/pharmexec/Europe%3A+Symons/A-True-Industry-Academia-Model/ArticleStandard/Article/detail/603324?contextCategoryId=48330&amp;ref=25</link>

    <description>Industry is working more innovatively with academia on 'front-end' drug discovery. Gerhard Symons asks
    what this entails, and what are the challenges and rewards of this nascent paradigm?</description>

    <dc:date>2009-01-27T05:00:00Z</dc:date>

    <EMSArticle:flashImageUrl>
    http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/242009/603324null</EMSArticle:flashImageUrl>

    <EMSArticle:contentFormat>HTML</EMSArticle:contentFormat>
  </item>
</rdf:RDF>


